Lotus Pharmaceutical Statistics

Total Valuation

Lotus Pharmaceutical has a market cap or net worth of TWD 71.39 billion. The enterprise value is 80.14 billion.

Market Cap	71.39B
Enterprise Value	80.14B

Important Dates

The next estimated earnings date is Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	Aug 5, 2024

Share Statistics

Lotus Pharmaceutical has 265.39 million shares outstanding. The number of shares has increased by 0.37% in one year.

Current Share Class	n/a
Shares Outstanding	265.39M
Shares Change (YoY)	+0.37%
Shares Change (QoQ)	-0.06%
Owned by Insiders (%)	0.64%
Owned by Institutions (%)	6.16%
Float	158.81M

Valuation Ratios

The trailing PE ratio is 16.32 and the forward PE ratio is 12.03.

PE Ratio	16.32
Forward PE	12.03
PS Ratio	4.00
PB Ratio	3.53
P/TBV Ratio	8.38
P/FCF Ratio	16.54
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.16, with an EV/FCF ratio of 18.57.

EV / Earnings	18.50
EV / Sales	4.56
EV / EBITDA	12.16
EV / EBIT	15.05
EV / FCF	18.57

Financial Position

The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.62.

Current Ratio	2.54
Quick Ratio	1.80
Debt / Equity	0.62
Debt / EBITDA	1.89
Debt / FCF	2.88
Interest Coverage	9.24

Financial Efficiency

Return on equity (ROE) is 23.42% and return on invested capital (ROIC) is 10.87%.

Return on Equity (ROE)	23.42%
Return on Assets (ROA)	9.48%
Return on Capital (ROIC)	10.87%
Revenue Per Employee	16.01M
Profits Per Employee	3.94M
Employee Count	1,099
Asset Turnover	0.50
Inventory Turnover	1.94

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.18% in the last 52 weeks. The beta is 0.52, so Lotus Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	-2.18%
50-Day Moving Average	271.68
200-Day Moving Average	282.58
Relative Strength Index (RSI)	44.33
Average Volume (20 Days)	1,338,851

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Lotus Pharmaceutical had revenue of TWD 17.59 billion and earned 4.33 billion in profits. Earnings per share was 16.48.

Revenue	17.59B
Gross Profit	9.92B
Operating Income	5.32B
Pretax Income	5.37B
Net Income	4.33B
EBITDA	6.47B
EBIT	5.32B
Earnings Per Share (EPS)	16.48

Full Income Statement

Balance Sheet

The company has 3.69 billion in cash and 12.44 billion in debt, giving a net cash position of -8.75 billion or -32.98 per share.

Cash & Cash Equivalents	3.69B
Total Debt	12.44B
Net Cash	-8.75B
Net Cash Per Share	-32.98
Equity (Book Value)	20.22B
Book Value Per Share	76.24
Working Capital	9.45B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.62 billion and capital expenditures -305.49 million, giving a free cash flow of 4.32 billion.

Operating Cash Flow	4.62B
Capital Expenditures	-305.49M
Free Cash Flow	4.32B
FCF Per Share	16.26

Full Cash Flow Statement

Margins

Gross margin is 56.39%, with operating and profit margins of 30.26% and 24.63%.

Gross Margin	56.39%
Operating Margin	30.26%
Pretax Margin	30.54%
Profit Margin	24.63%
EBITDA Margin	36.75%
EBIT Margin	30.26%
FCF Margin	24.53%

Dividends & Yields

This stock pays an annual dividend of 4.65, which amounts to a dividend yield of 1.76%.

Dividend Per Share	4.65
Dividend Yield	1.76%
Dividend Growth (YoY)	34.32%
Years of Dividend Growth	4
Payout Ratio	28.43%
Buyback Yield	-0.37%
Shareholder Yield	1.39%
Earnings Yield	6.13%
FCF Yield	6.05%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Lotus Pharmaceutical has an Altman Z-Score of 4.27.

Altman Z-Score	4.27
Piotroski F-Score	n/a